If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-30. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
The station is at 750 m (2,460 ft) and the surrounding mountains at 1,100 m (3,600 ft), causing cold air to pool in the valley: recent studies show that winter temperatures in the area increase with elevation by as much as 10 °C (18 °F). The average temperature in Oymyakon has risen about 2.7 degrees Celsius since preindustrial times. On December 22, 1991, the Klinck Automatic Weather Station (AWS) (located at 72°31′N 40°48′W, altitude 3,105 metres (10,187 ft)) in Greenland recorded a temperature of −69.6 °C (−93.3 °F). The WMO validated the metadata and observations and was able to conclude that the observation was credible in terms of instrument calibration, monitoring of the station and the synoptic situation. The WMO Rapporteur accepted the observation as the officially lowest observed near‐surface air temperature for the Northern and Western Hemispheres.
Firm tofu (called 老豆腐 lǎodòufu in Chinese; 木綿豆腐, momen-dōfu in Japanese, "cotton tofu"; 모두부, mo-dubu in Korean): Although drained and pressed, this form of fresh tofu retains a high moisture content. It has the firmness of raw meat and bounces back readily when pressed. The texture of the inside of the tofu is similar to that of a firm custard. The skin of this form of tofu retains the pattern of the muslin used to drain it, and the outside is slightly more resistant to damage than the inside. It can be picked up easily with chopsticks. A very firm type of momen-dōfu is eaten in parts of Japan, called ishi-dōfu (石豆腐, "stone tofu") in parts of Ishikawa, or iwa-dōfu (岩豆腐, "rock tofu") in Gokayama in the Toyama Prefecture and in Iya in the prefecture of Tokushima. These types of firm tofu are produced with seawater instead of nigari (magnesium chloride), or using concentrated soy milk. Some of them are squeezed using heavy weights to eliminate excess moisture. These products are produced in areas where traveling is inconvenient, such as remote islands, mountain villages, and heavy snowfall areas.
Rees Pughe in Denbighshire and takes the surname "Pughe". Anthony Bushby Bacon sells his share of the Hirwaun ironworks to his brother Thomas and buys the Mathews' estate at Aberaman. Julia Ann Hatton moves to Kidwelly after her husband's death. A stone-built Caerleon Bridge is opened. A new bridge is built across the River Dyfi at Machynlleth. Thomas Jones of Denbigh marries for a third time, to Mary Lloyd. The Prince of Wales makes an impromptu visit to Wales in the company of Sir Richard Puleston. To commemorate the event, he plants a young oak tree.
==== Addiction ==== Arguably, some people pursue ineffective shortcuts to feeling good. These shortcuts create positive feelings, but are problematic, in part because of the lack of effort involved. Some examples of these shortcuts include shopping, drugs, chocolate, loveless sex, and TV. These are problematic pursuits because all of these examples have the ability to become addictive. When happiness comes to us so easily, it comes with a price we may not realize. This price comes when taking these shortcuts is the only way to become happy, otherwise viewed as an addiction. A review by Amy Krentzman on the Application of Positive Psychology to Substance Use, Addiction, and Recovery Research, identified, in the field of positive psychology, three domains that allow an individual to thrive and contribute to society. One of these, A Pleasant Life, involves good feelings about the past, present, and future. To tie this with addiction, they chose an example of alcoholism. Research on positive affect and alcohol showed a majority of the population associates drinking with pleasure. The pleasure one feels from alcohol is known as somatic pleasure, which is immediate but a short lived sensory delight. The researchers wanted to make clear pleasure alone does not amount to a life well lived; there is more to life than pleasure. Secondly, the Engaged Life is associated with positive traits such as strength of character.
Sources: en.wikipedia.org
==== 2016: Redshirt season ==== Following his matriculation at the University of Oregon in the spring of 2016, McCormick redshirted his freshman season while recovering from his knee injury. By August 2016, McCormick had been cleared to fully participate in football activities, though he was required to wear a knee brace. In September 2016, McCormick told The Oregonian that the brace may be blunting his speed, owing to the brace's impact on his natural running motion.
The officials further add that the PAF conducted airstrikes at 46 locations inside Afghanistan. The officials also released footage that they said showed Pakistani troops crossing into Afghanistan from North Waziristan and capturing a border outpost belonging to Afghan Taliban. Elsewhere, Pakistan's security forces claimed to have taken control of 32 square kilometres (12 sq mi) of strategic Afghan territory south of the Zhob sector. This strategic territory, near the Kandahar Province, is known as the Ghudwana enclave. At night, local resident in Herat province said that fighter jets were patrolling the skies of the province. In Islam Qala, residents reported hearing two explosions as aircraft flew over. At the same time, armed clashes resumed between Taliban and Pakistan border guards along the border area of Angoor Adda. On 2 March, the PAF conducted airstrikes in Kabul which were confirmed by Taliban officials. According to Afghan local sources, the PAF also carried out airstrikes in parts of Panjshir, Kapisa, and Nangarhar provinces. In the provinces of Panjshir and Kapisa, local sources reported that, for the third consecutive night, they had heard aircraft, explosions, and ground-to-air gunfire. According to residents, scattered gunfire was also heard in the area known as Darband Mountain, which connects Panjshir, Kapisa, and Parwan. While in Nangarhar province, Pakistan's warplane bombed a Taliban-led Afghan armed forces' border brigade near the provincial capital Jalalabad.
=== System IV === Four membrane proteins are necessary for the attachment of a heme in cytochrome b6. A major difference to systems I-III is that the heme attachment occurs at the opposite side of the lipid bilayer compared to the other systems.
Sources: en.wikipedia.org
=== Amino-acid shuttles and the transport of ammonia === Since diffusion and transport of free ammonia across the cell membrane will affect the pH level of the cell, the more attractive and regulated way of transporting ammonia between the neuronal and the astrocytic compartment is via an amino-acid shuttle, of which there are two: leucine and alanine. The amino acid moves in the opposite direction of glutamine. In the opposite direction of the amino acid, a corresponding molecule is transported; for alanine this molecule is lactate; for leucine, α-ketoisocaproate.
Meanwhile, in 1843, James Prescott Joule independently discovered the mechanical equivalent in a series of experiments. In one of them, now called the "Joule apparatus", a descending weight attached to a string caused a paddle immersed in water to rotate. He showed that the gravitational potential energy lost by the weight in descending was equal to the internal energy gained by the water through friction with the paddle. Over the period 1840–1843, similar work was carried out by engineer Ludwig A. Colding, although it was little known outside his native Denmark. Both Joule's and Mayer's work suffered from resistance and neglect but it was Joule's that eventually drew the wider recognition.
Techniques to preserve birds were attempted even from the early 16th century as shown in the writings of Conrad Gesner and Pierre Belon. Belon provided instructions on the removal of viscera and the use of salt to preserve bird specimens in his 1555 book on birds. These were further improved in the 17th century and a range of preservatives included ash (potassium carbonate), salt, sulphur, alum, alcohol and various plant extracts were used. In the early days of bird collections, most specimens were mounted in unrealistic positions often with their wings raised as if they were about to take flight. These were kept in the open and the colours were prone to fading and the specimens themselves prone to damage by beetles. In Berlin, J. L. Frisch started using tightly enclosed glass jars for every mount to prevent pest damage. During this time, Comte de Reaumur at the Paris Museum had managed to find techniques to preserve specimens dry and without loss of colour. This technique was however a secret and similar results were later achieved by pickling using salt, ground pepper and alum and drying for a month with threads holding the bird in a natural position. The use of arsenic to preserve specimens was first introduced by Jean-Baptiste Bécoeur (1718-1777) but this method was publicly revealed only in 1800 by Louis Dufresne in Daudin's Traité Élémentaire et Complet d’Ornithologie (1800). In modern collections, salvaged or collected birds may be preserved in a number of ways.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.